F-10POS: Oncolytics Biotech Withdraws Unsold Securities from Registration
Securities Withdrawal
Oncolytics Biotech files post-effective amendment to withdraw unsold securities from multiple prior registration statements, revising effectiveness date for remaining registrations.
Summary
- Oncolytics Biotech Inc. has filed a post-effective amendment to several of its Form F-10 registration statements.
- The primary purpose of this filing is to withdraw the unsold portion of securities that were previously registered.
- This action pertains to multiple registration statements filed between 2007 and 2024, covering various securities including units, common shares, subscription receipts, warrants, and debt securities.
- The filing also revises the designated effectiveness date and time for the remaining registrations to April 8, 2026, at 4:30 p.m. Eastern time.
- No other changes have been made to the registration statements as previously amended.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it indicates that previously registered securities were not sold, suggesting potential challenges in capital raising or market reception for those offerings.
Negatives
- The company is withdrawing previously registered securities, indicating they were not sold as anticipated.
Future Outlook
The filing does not provide forward-looking statements or guidance; it pertains to the withdrawal of previously registered but unsold securities and the adjustment of effectiveness dates for remaining registrations.
Industry Context
StockSavvy.ai notes that this filing is administrative in nature, related to the management of past securities offerings rather than current operational or financial performance. Companies often adjust or withdraw registrations for securities that are no longer intended for issuance or have not been sold within expected timelines.
Stakeholder Impact
- Shareholders: The withdrawal of unsold securities may indirectly impact future capital raising efforts and dilution potential, though the immediate impact is likely minimal as these securities were not sold.
Next Steps
- The withdrawal of unsold securities from the specified registration statements.
- The revised effectiveness date of April 8, 2026, for the remaining registered securities.
Key Dates
| Date | Description |
|---|---|
| February 2, 2007 | Initial filing date for Registration Statement No. 333-140460. |
| February 8, 2007 | Initial filing date for Registration Statement No. 333-140529. |
| June 6, 2008 | Initial filing date for Registration Statement No. 333-151513. |
| June 2, 2010 | Initial filing date for Registration Statement No. 333-167250. |
| June 21, 2012 | Initial filing date for Registration Statement No. 333-182260. |
| July 25, 2014 | Initial filing date for Registration Statement No. 333-197633. |
| April 25, 2018 | Initial filing date for Registration Statement No. 333-224432. |
| June 8, 2020 | Initial filing date for Registration Statement No. 333-239025. |
| June 10, 2022 | Initial filing date for Registration Statement No. 333-265510. |
| July 25, 2024 | Initial filing date for Registration Statement No. 333-281009. |
| April 6, 2026 | Date of filing of Post-Effective Amendment No. 2 to the Registration Statements. |
| April 8, 2026 | Revised designated effectiveness date and time for the registration statements. |
Keywords
Oncolytics Biotech, SEC Filing, Form F-10, Registration Statement, Securities Withdrawal, Post-Effective Amendment, Unsold Securities, Capital Markets
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.